Literature DB >> 22892530

Newborn screening for cystic fibrosis: Polish 4 years' experience with CFTR sequencing strategy.

Agnieszka Sobczyńska-Tomaszewska1, Mariusz Ołtarzewski, Kamila Czerska, Katarzyna Wertheim-Tysarowska, Dorota Sands, Jarosław Walkowiak, Jerzy Bal, Tadeusz Mazurczak.   

Abstract

Newborn screening for cystic fibrosis (NBS CF) in Poland was started in September 2006. Summary from 4 years' experience is presented in this study. The immunoreactive trypsin/DNA sequencing strategy was implemented. The group of 1,212,487 newborns were screened for cystic fibrosis during the programme. We identified a total of 221 CF cases during this period, including, 4 CF cases were reported to be omitted by NBS CF. Disease incidence in Poland based on the programme results was estimated as 1/4394 and carrier frequency as 1/33. The frequency of the F508del was similar (62%) to population data previously reported. This strategy allowed us to identify 29 affected infants with rare genotypes. The frequency of some mutations (eg, 2184insA, K710X) was assessed in Poland for the first time. Thus, sequencing assay seems to be accurate method for screening programme using blood spots in the Polish population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892530      PMCID: PMC3598320          DOI: 10.1038/ejhg.2012.180

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  29 in total

1.  Changes in fertility and family sizes in Europe.

Authors:  D Pearce; G Cantisani; A Laihonen
Journal:  Popul Trends       Date:  1999

2.  [Analysis of mutations in the CFTR gene in patients diagnosed with cystic fibrosis in Poland].

Authors:  I Aznarez; J Bal; T Casals; X Estivill; N Moral; D Sands; V Nunes; A Sobczyńska-Tomaszewska; L C Tsui; J Zielenski
Journal:  Med Wieku Rozwoj       Date:  2000 Apr-Jun

3.  Bilateral sweat tests with two different methods as a part of cystic fibrosis newborn screening (CF NBS) protocol and additional quality control.

Authors:  Dorota Sands; Mariusz Ołtarzewski; Anna Nowakowska; Katarzyna Zybert
Journal:  Folia Histochem Cytobiol       Date:  2010-09-30       Impact factor: 1.698

4.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

5.  Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond.

Authors:  Drucy Borowitz; Richard B Parad; Jack K Sharp; Kathryn A Sabadosa; Karen A Robinson; Michael J Rock; Philip M Farrell; Marci K Sontag; Margaret Rosenfeld; Stephanie D Davis; Bruce C Marshall; Frank J Accurso
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

6.  Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing.

Authors:  Annie Dupuis; David Hamilton; David E C Cole; Mary Corey
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

7.  Assay of serum immunoreactive trypsin in dried blood spots and the early detection of cystic fibrosis.

Authors:  H C Ryley; P G Robinson; Y Yamashiro; D M Bradley
Journal:  J Clin Pathol       Date:  1981-08       Impact factor: 3.411

8.  Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.

Authors:  E Ranieri; R G Ryall; C P Morris; P V Nelson; W F Carey; A C Pollard; E F Robertson
Journal:  BMJ       Date:  1991-05-25

9.  Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Authors:  J Zielenski; R Rozmahel; D Bozon; B Kerem; Z Grzelczak; J R Riordan; J Rommens; L C Tsui
Journal:  Genomics       Date:  1991-05       Impact factor: 5.736

10.  Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis.

Authors:  Charles M Strom; Beryl Crossley; Arlene Buller-Buerkle; Michael Jarvis; Franklin Quan; Mei Peng; Kasinathan Muralidharan; Victoria Pratt; Joy B Redman; Weimin Sun
Journal:  Genet Med       Date:  2011-02       Impact factor: 8.822

View more
  14 in total

1.  DeltaF508 CFTR Hetero- and Homozygous Paediatric Patients with Cystic Fibrosis Do Not Differ with Regard to Nutritional Status.

Authors:  Aleksandra Mędza; Katarzyna Kaźmierska; Bartosz Wielgomas; Lucyna Konieczna; Ilona Olędzka; Agnieszka Szlagatys-Sidorkiewicz; Katarzyna Sznurkowska
Journal:  Nutrients       Date:  2021-04-21       Impact factor: 5.717

2.  Deep resequencing of CFTR in 762 F508del homozygotes reveals clusters of non-coding variants associated with cystic fibrosis disease traits.

Authors:  Briana Vecchio-Pagán; Scott M Blackman; Melissa Lee; Melis Atalar; Matthew J Pellicore; Rhonda G Pace; Arianna L Franca; Karen S Raraigh; Neeraj Sharma; Michael R Knowles; Garry R Cutting
Journal:  Hum Genome Var       Date:  2016-11-24

3.  Targeted sequencing reveals complex, phenotype-correlated genotypes in cystic fibrosis.

Authors:  Maxim Ivanov; Alina Matsvay; Olga Glazova; Stanislav Krasovskiy; Mariya Usacheva; Elena Amelina; Aleksandr Chernyak; Mikhail Ivanov; Sergey Musienko; Timofey Prodanov; Sergey Kovalenko; Ancha Baranova; Kamil Khafizov
Journal:  BMC Med Genomics       Date:  2018-02-13       Impact factor: 3.063

Review 4.  Splicing mutations in human genetic disorders: examples, detection, and confirmation.

Authors:  Abramowicz Anna; Gos Monika
Journal:  J Appl Genet       Date:  2018-04-21       Impact factor: 3.240

5.  Phenotypic spectrum and genetic heterogeneity of cystic fibrosis in Sri Lanka.

Authors:  Neluwa Liyanage Ruwan Indika; Dinesha Maduri Vidanapathirana; Hewa Warawitage Dilanthi; Grace Angeline Malarnangai Kularatnam; Nambage Dona Priyani Dhammika Chandrasiri; Eresha Jasinge
Journal:  BMC Med Genet       Date:  2019-05-24       Impact factor: 2.103

Review 6.  Newborn Screening for CF across the Globe-Where Is It Worthwhile?

Authors:  Virginie Scotet; Hector Gutierrez; Philip M Farrell
Journal:  Int J Neonatal Screen       Date:  2020-03-04

7.  Leukocyte Telomere Length Is Not Reduced in Children and Adults with Cystic Fibrosis but Associates with Clinical Characteristics-A Cross-Sectional Study.

Authors:  Aleksandra Glapa-Nowak; Shivaprakash Jagalur Mutt; Aleksandra Lisowska; Ewa Sapiejka; Joanna Goździk-Spychalska; Mirosława Wieczorek-Filipiak; Sławomira Drzymała-Czyż; Jan Krzysztof Nowak; Olaf Thalmann; Karl-Heinz Herzig; Jarosław Walkowiak
Journal:  J Clin Med       Date:  2021-02-04       Impact factor: 4.241

8.  Impact of newborn screening for cystic fibrosis on clinical outcomes of pediatric patients: 10 years' experience in Lodz Voivodship.

Authors:  M Olszowiec-Chlebna; E Mospinek; J Jerzynska
Journal:  Ital J Pediatr       Date:  2021-04-09       Impact factor: 2.638

9.  Screening for cystic fibrosis in New York State: considerations for algorithm improvements.

Authors:  Denise M Kay; Breanne Maloney; Rhonda Hamel; Melissa Pearce; Lenore DeMartino; Rebecca McMahon; Emily McGrath; Lea Krein; Beth Vogel; Carlos A Saavedra-Matiz; Michele Caggana; Norma P Tavakoli
Journal:  Eur J Pediatr       Date:  2015-08-21       Impact factor: 3.183

Review 10.  Genetic Testing in the Diagnosis of Primary Ciliary Dyskinesia: State-of-the-Art and Future Perspectives.

Authors:  Samuel A Collins; Woolf T Walker; Jane S Lucas
Journal:  J Clin Med       Date:  2014-05-09       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.